Francesco Ceppi

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


41 publications

2024 | 2023 | 2022 | 2021 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2009 |
2024
 
Characteristics and treatment of acute myeloid neoplasms with cutaneous involvement in infants up to 6 months of age: A retrospective study.
Renaud J., Goemans B.F., Locatelli F., Pigazzi M., Redmond S., Kuehni C.E., Destaillats A., Alonzo T.A., Gerbing R.B., Gamis A. et al., 2024/04/14. Pediatric blood & cancer pp. e31006. Peer-reviewed.
[DOI][Pmid][serval:BIB_CCB2557653E6]
 
INSPIRED Symposium Part 4B: Chimeric Antigen Receptor T Cell Correlative Studies-Established Findings and Future Priorities.
Ligon J.A., Ramakrishna S., Ceppi F., Calkoen FGJ, Diorio C., Davis K.L., Jacoby E., Gottschalk S., Schultz L.M., Capitini C.M., 2024/02. Transplantation and cellular therapy, 30 (2) pp. 155-170. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5AD3A4CAB622]
2023
Differentiation between rebound thymic hyperplasia and thymic relapse after chemotherapy in pediatric Hodgkin lymphoma.
Franke F.C., Damek A., Steglich J., Kurch L., Hasenclever D., Georgi T.W., Wohlgemuth W.A., Mauz-Körholz C., Körholz D., Kluge R. et al., 2023/08. Pediatric blood & cancer, 70 (8) pp. e30421. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_92DF574D1785]
 
How should childhood acute lymphoblastic leukemia relapses in low-income and middle-income countries be managed: The AHOPCA-ALL study group experience.
Espinoza D., Blanco Lopez J.G., Vasquez R., Fu L., Martínez R., Rodríguez H., Navarrete M., Howard S.C., Friedrich P., Valsecchi M.G. et al., 2023/03/01. Cancer, 129 (5) pp. 771-779. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D90FC303F69C]
Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study.
Mauz-Körholz C., Landman-Parker J., Fernández-Teijeiro A., Attarbaschi A., Balwierz W., Bartelt J.M., Beishuizen A., Boudjemaa S., Cepelova M., Ceppi F. et al., 2023/03. The Lancet. Oncology, 24 (3) pp. 252-261. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3E3F320DAA60]
 
Médecine de précision dans le traitement des cancers pédiatriques [Precision medicine in the treatment of pediatric cancers]
Ben Hassine K., Ceppi F., Baleydier F., Von Bueren A.O., Beck Popovic M., Ansari M., 2023/02/22. Revue medicale suisse, 19 (815) pp. 380-387. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_8E7BBA220C93]
2022
 
Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward.
Jenei K., Aziz Z., Booth C., Cappello B., Ceppi F., de Vries EGE, Fojo A., Gyawali B., Ilbawi A., Lombe D. et al., 2022/12. The Lancet. Global health, 10 (12) pp. e1860-e1866. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A5D2D166DA1B]
 
Near-tetraploid T-cell acute lymphoblastic leukaemia in childhood: Results of the AIEOP-BFM ALL studies.
Ceppi F., Gotti G., Möricke A., Silvestri D., Poyer F., Lentes J., Bergmann A., Trka J., Alten J., Elitzur S. et al., 2022/11. European journal of cancer, 175 pp. 120-124. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_017CC4FF5C4F]
 
Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult Subjects.
Ceppi F., Wilson A.L., Annesley C., Kimmerly G.R., Summers C., Brand A., Seidel K., Wu Q.V., Beebe A., Brown C. et al., 2022/07/01. Cancer immunology research, 10 (7) pp. 856-870. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FC5F316AD054]
Are clinical pharmacology studies still needed in childhood acute lymphoblastic leukemia?
Conter V., Ceppi F., 2022/02/01. Haematologica, 107 (2) pp. 356-357. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2D3CE95B7D60]
2021
 
Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells.
Lichtenstein D.A., Schischlik F., Shao L., Steinberg S.M., Yates B., Wang H.W., Wang Y., Inglefield J., Dulau-Florea A., Ceppi F. et al., 2021/12/16. Blood, 138 (24) pp. 2469-2484. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_05643E176D97]
 
Utilizing the prognostic impact of minimal residual disease in treatment decisions for pediatric acute lymphoblastic leukemia.
Ceppi F., Rizzati F., Colombini A., Conter V., Cazzaniga G., 2021/09. Expert review of hematology, 14 (9) pp. 795-807. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A38A06E46860]
 
Spontaneous Partial Remission in a Child With B-Lineage Acute Lymphoblastic Leukemia and Chickenpox: A Role For Acyclovir?
Chtioui H., Ceppi F., Renella R., Diezi M., 2021/07/01. Journal of pediatric hematology/oncology, 43 (5) pp. e711-e714. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4886CE725DDF]
 
Assessment of Waldeyer's ring in pediatric and adolescent Hodgkin lymphoma patients-Importance of multimodality imaging: Results from the EuroNet-PHL-C1 trial.
Kurch L., Mauz-Körholz C., Fosså A., Georgi T.W., Kluge R., Bartelt J.M., Kunze C., Wohlgemuth W.A., Pelz T., Vordermark D. et al., 2021/04. Pediatric blood & cancer, 68 (4) pp. e28903. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DBD0CBB22042]
 
Comparison of Interim PET Response to Second-Line Versus First-Line Treatment in Classic Hodgkin Lymphoma: Contribution to the Development of Response Criteria for Relapsed or Progressive Disease.
Kluge R., Wittig T., Georgi T.W., Kurch L., Sabri O., Wallace W.H., Klekawka T., Fernández-Teijeiro A., Ceppi F., Karlén J. et al., 2021/03. Journal of nuclear medicine, 62 (3) pp. 338-341. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_12F206B3374D]
 
Second malignant neoplasms after treatment of non-Hodgkin's lymphoma-a retrospective multinational study of 189 children and adolescents.
Attarbaschi A., Carraro E., Ronceray L., Andrés M., Barzilai-Birenboim S., Bomken S., Brugières L., Burkhardt B., Ceppi F., Chiang AKS et al., 2021/02. Leukemia, 35 (2) pp. 534-549. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DF447B7F2FE0]
2019
 
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.
Gardner RA, Ceppi F, Rivers J, Annesley C, Summers C, Taraseviciute A, Gust J, Leger KJ, Tarlock K, Cooper TM et al., 2019/12. Blood.
[DOI][Pmid][serval:BIB_D78498D9E7E1]
 
Primary central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescents.
Attarbaschi A, Abla O, Ronceray L, Bansil S, Bomken S, Burkhardt B, Ceppi F, Chiang AKS, Dave H, Fedorova A et al., 2019/12. Blood advances, 3 (24) pp. 4291-4297.
[DOI][Pmid][serval:BIB_B4091481F6E4]
 
Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia.
Ceppi F, Gardner RA, 2019/05. Cancer journal (Sudbury, Mass.).
[DOI][Pmid][serval:BIB_879BDB661A72]
 
Progrès récents et orientations futures de la thérapie avec cellules CAR-T en oncologie pédiatrique [Recent advances and future directions in CAR-T cell therapy in pediatric oncology]
Ceppi F., Renella R., Diezi M., Ansari M., Duchosal M.A., Arber C., Kandalaft L., Coukos G., Beck-Popovic M., 2019/01/09. Revue medicale suisse, 15 (N° 632-633) pp. 85-91. Peer-reviewed.
[Pmid][serval:BIB_556228939270]
2018
Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.
Sun W., Malvar J., Sposto R., Verma A., Wilkes J.J., Dennis R., Heym K., Laetsch T.W., Widener M., Rheingold S.R. et al., 2018/11. Leukemia, 32 (11) pp. 2316-2325. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8FC71E831A84]
 
Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using whole-exome sequencing.
Abaji R, Ceppi F, Patel S, Gagné V, Xu CJ, Spinella JF, Colombini A, Parasole R, Buldini B, Basso G et al., 2018/09. Pharmacogenomics, 19 (15) pp. 1181-1193.
[DOI][Pmid][serval:BIB_4166AD5A3BB1]
 
Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma.
Ceppi F, Rivers J, Annesley C, Pinto N, Park JR, Lindgren C, Mgebroff S, Linn N, Delaney M, Gardner RA, 2018/03. Transfusion, 58 (6) pp. 1414-1420.
[DOI][Pmid][serval:BIB_E62050C02A07]
Oral Nutritional Supplementation in Children Treated for Cancer in Low- and Middle-Income Countries Is Feasible and Effective: the Experience of the Children's Hospital Manuel De Jesus Rivera "La Mascota" in Nicaragua.
Peccatori N., Ortiz R., Rossi E., Calderon P., Conter V., García Y., Biondi A., Espinoza D., Ceppi F., Mendieta L. et al., 2018. Mediterranean journal of hematology and infectious diseases, 10 (1) pp. e2018038. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CB530B8B76CD]
2017
 
DNA variants in DHFR gene and response to treatment in children with childhood B ALL: revisited in AIEOP-BFM protocol.
Ceppi F, Gagné V, Douyon L, Quintin CJ, Colombini A, Parasole R, Buldini B, Basso G, Conter V, Cazzaniga G et al., 2017/12. Pharmacogenomics.
[DOI][Pmid][serval:BIB_EDC6EC764C81]
 
The Evolution and Future of CAR T Cells for B-Cell Acute Lymphoblastic Leukemia.
Annesley CE, Summers C, Ceppi F, Gardner RA, 2017/12. Clinical pharmacology and therapeutics.
[DOI][Pmid][serval:BIB_83DDACDECA35]
 
Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot.
Ceppi F., Beck-Popovic M., Bourquin J. P., Renella R., 2017/08. European journal of pediatrics, 176 (9) pp. 1163-1172.
[DOI][Pmid][serval:BIB_373A5D0422C1]
 
Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients.
Abaji R, Gagné V, Xu CJ, Spinella JF, Ceppi F, Laverdière C, Leclerc JM, Sallan SE, Neuberg D, Kutok JL et al., 2017/07. Oncotarget.
[DOI][Pmid][serval:BIB_78664D580492]
2016
 
Improvement of the Outcome of Relapsed or Refractory Acute Lymphoblastic Leukemia in Children Using a Risk-Based Treatment Strategy.
Ceppi F, Duval M, Leclerc JM, Laverdiere C, Delva YL, Cellot S, Teira P, Bittencourt H, 2016/09. PloS one.
[DOI][Pmid][serval:BIB_2EBE12379F1A]
 
Clinical presentation and risk factors of serious infections in children with Down syndrome treated for acute lymphoblastic leukemia.
Ceppi F, Stephens D, den Hollander BS, Krueger J, Whitlock J, Sung L, Hitzler J, 2016/07. Pediatric blood & cancer.
[DOI][Pmid][serval:BIB_58E47921EFCE]
 
Primary Cutaneous Lymphomas in Children and Adolescents.
Ceppi F, Pope E, Ngan B, Abla O, 2016/05. Pediatric blood & cancer.
[DOI][Pmid][serval:BIB_4CEFC3FF81BC]
 
Safety and efficacy of intrathecal rituximab in children with B cell lymphoid CD20+ malignancies: An international retrospective study.
Ceppi F, Weitzman S, Woessmann W, Davies K, Lassaletta A, Reismüller B, Mellgren K, Uyttebroeck A, Maia I, Abdullah S et al., 2016/04. American journal of hematology.
[DOI][Pmid][serval:BIB_645BA104D6CE]
2015
 
Anaplastic Large Cell Lymphoma in Central America: A Report From the Central American Association of Pediatric Hematology Oncology (AHOPCA).
Ceppi F, Ortiz R, Antillón F, Vasquez R, Gomez W, Gamboa J, Garrido C, Chantada G, Peña A, Gupta S, 2015/08. Pediatric blood & cancer.
[DOI][Pmid][serval:BIB_FFED0AF20B2B]
 
Infectious complications in children with acute lymphoblastic leukemia treated in low-middle-income countries.
Caniza MA, Odio C, Mukkada S, Gonzalez M, Ceppi F, Chaisavaneeyakorn S, Apiwattanakul N, Howard SC, Conter V, Bonilla M, 2015/07. Expert review of hematology.
[DOI][Pmid][serval:BIB_9BB3339BD23D]
 
Supportive medical care for children with acute lymphoblastic leukemia in low- and middle-income countries.
Ceppi F, Antillon F, Pacheco C, Sullivan CE, Lam CG, Howard SC, Conter V, 2015/05. Expert review of hematology.
[DOI][Pmid][serval:BIB_723AE94EE840]
2014
 
Risk factors for relapse in childhood acute lymphoblastic leukemia: prediction and prevention.
Ceppi F, Cazzaniga G, Colombini A, Biondi A, Conter V, 2014/11. Expert review of hematology.
[URN][DOI][Pmid][serval:BIB_0100233D2D61]
 
Calcineurin inhibitor-free graft-versus-host disease prophylaxis with sirolimus and mycophenolate mofetil in a second allogeneic stem cell transplantation for engraftment failure and rituximab-refractory Epstein-Barr virus-induced posttransplant lymphoproliferative disease.
Ceppi F., Duval M., Teira P., Therrien R., Ovetchkine P., Mallette B., Bittencourt H., 2014/07. Journal of pediatric hematology/oncology, 36 (5) pp. e319-21. Peer-reviewed.
[DOI][Pmid][serval:BIB_2216DA1C6D68]
 
Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia.
Ben Tanfous M, Sharif-Askari B, Ceppi F, Laaribi H, Gagné V, Rousseau J, Labuda M, Silverman LB, Sallan SE, Neuberg D et al., 2014/06. Clinical cancer research : an official journal of the American Association for Cancer Research.
[DOI][Pmid][serval:BIB_D030F4FC87F7]
 
Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia.
Ceppi F, Langlois-Pelletier C, Gagné V, Rousseau J, Ciolino C, De Lorenzo S, Kevin KM, Cijov D, Sallan SE, Silverman LB et al., 2014/06. Pharmacogenomics.
[DOI][Pmid][serval:BIB_E1BC66BD5F4E]
2013
 
Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia.
Gagné V, Rousseau J, Labuda M, Sharif-Askari B, Brukner I, Laverdière C, Ceppi F, Sallan SE, Silverman LB, Neuberg D et al., 2013/08. Clinical cancer research : an official journal of the American Association for Cancer Research.
[DOI][Pmid][serval:BIB_4EB35944E14C]
2009
 
Cytogenetic characterization of childhood acute lymphoblastic leukemia in Nicaragua.
Ceppi F, Brown A, Betts DR, Niggli F, Popovic MB, 2009/12. Pediatric blood & cancer.
[DOI][WoS][Pmid][serval:BIB_6FD8206C6DB1]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University